Your browser doesn't support javascript.
loading
CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS.
Sakemura, R Leo; Manriquez Roman, Claudia; Horvei, Paulina; Siegler, Elizabeth L; Girsch, James H; Sirpilla, Olivia L; Stewart, Carli M; Yun, Kun; Can, Ismail; Ogbodo, Ekene J; Adada, Mohamad M; Bezerra, Evandro D; Kankeu Fonkoua, Lionel Aurelien; Hefazi, Mehrdad; Ruff, Michael W; Kimball, Brooke L; Mai, Long K; Huynh, Truc N; Nevala, Wendy K; Ilieva, Kristina; Augsberger, Christian; Patra-Kneuer, Maria; Schanzer, Jürgen; Endell, Jan; Heitmüller, Christina; Steidl, Stefan; Parikh, Sameer A; Ding, Wei; Kay, Neil E; Nowakowski, Grzegorz S; Kenderian, Saad S.
Afiliação
  • Sakemura RL; T Cell Engineering, Mayo Clinic, Rochester, MN.
  • Manriquez Roman C; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Horvei P; T Cell Engineering, Mayo Clinic, Rochester, MN.
  • Siegler EL; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Girsch JH; Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN.
  • Sirpilla OL; Department of Molecular Medicine, Mayo Clinic, Rochester, MN.
  • Stewart CM; T Cell Engineering, Mayo Clinic, Rochester, MN.
  • Yun K; Pediatric Bone Marrow Transplant and Cellular Therapy, UPMC Children's Hospital of Pittsburgh, PA.
  • Can I; T Cell Engineering, Mayo Clinic, Rochester, MN.
  • Ogbodo EJ; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Adada MM; T Cell Engineering, Mayo Clinic, Rochester, MN.
  • Bezerra ED; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Kankeu Fonkoua LA; Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN.
  • Hefazi M; Department of Molecular Medicine, Mayo Clinic, Rochester, MN.
  • Ruff MW; T Cell Engineering, Mayo Clinic, Rochester, MN.
  • Kimball BL; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Mai LK; Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN.
  • Huynh TN; Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, MN.
  • Nevala WK; T Cell Engineering, Mayo Clinic, Rochester, MN.
  • Ilieva K; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Augsberger C; Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN.
  • Patra-Kneuer M; Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, MN.
  • Schanzer J; T Cell Engineering, Mayo Clinic, Rochester, MN.
  • Endell J; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Heitmüller C; Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN.
  • Steidl S; Department of Molecular Medicine, Mayo Clinic, Rochester, MN.
  • Parikh SA; T Cell Engineering, Mayo Clinic, Rochester, MN.
  • Ding W; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Kay NE; Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN.
  • Nowakowski GS; T Cell Engineering, Mayo Clinic, Rochester, MN.
  • Kenderian SS; Division of Hematology, Mayo Clinic, Rochester, MN.
Blood ; 143(3): 258-271, 2024 Jan 18.
Article em En | MEDLINE | ID: mdl-37879074
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Monoclonais Humanizados / Imunoterapia Idioma: En Revista: Blood Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Mongólia
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Monoclonais Humanizados / Imunoterapia Idioma: En Revista: Blood Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Mongólia